Events
-
-
DUPIXENT®(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
Virtual (Zoom)
by Roopen Patel, MDJoin us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients…
-
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
Virtual (Zoom)
by Douglas DiRuggiero, PA-CThis program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
-
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
Virtual (Zoom)
by Ben Ehst, MDLearn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin…
-
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
Virtual (Zoom)
by Marc Serota, MDLearn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
-
-
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
Virtual (Zoom)
by Karan Lal, DOThis program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
-
DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
Virtual (Zoom)
by Omar Noor, MDJoin us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
-
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
Virtual (Zoom)
by Autumn Burnette, MDJoin us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation
-
Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
Virtual (Zoom)
by Amy Spizuoco, DOJoin us for a program discussing a real-world case of an adolescent patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation
-
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
Virtual (Zoom)
by Daniel Butler, MDLearn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations and a treatment option for appropriate BP patients
-
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
Virtual (Zoom)
by Leigh Ann Pansch, NPLearn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate CSU patients 12+ years of age